Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 340 Shares of Illumina, Inc. (NASDAQ:ILMN)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 35.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 630 shares of the life sciences company’s stock after selling 340 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Illumina were worth $90,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Global Retirement Partners LLC raised its holdings in shares of Illumina by 36.5% in the third quarter. Global Retirement Partners LLC now owns 714 shares of the life sciences company’s stock worth $99,000 after buying an additional 191 shares during the period. Avior Wealth Management LLC raised its holdings in shares of Illumina by 9.9% in the third quarter. Avior Wealth Management LLC now owns 3,327 shares of the life sciences company’s stock worth $457,000 after buying an additional 300 shares during the period. Royal Fund Management LLC raised its holdings in shares of Illumina by 5.9% in the third quarter. Royal Fund Management LLC now owns 5,702 shares of the life sciences company’s stock worth $783,000 after buying an additional 320 shares during the period. Riverview Trust Co increased its holdings in Illumina by 203.5% during the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in Illumina by 20.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 142,858 shares of the life sciences company’s stock worth $19,612,000 after purchasing an additional 24,365 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Up 3.5 %

ILMN stock opened at $124.46 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The business has a fifty day simple moving average of $132.79 and a 200-day simple moving average of $127.58. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $229.58.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.14 EPS. As a group, analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Insider Transactions at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the acquisition, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.17% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price target on shares of Illumina in a report on Tuesday, April 9th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research report on Thursday, January 4th. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.